Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: a morphological, immunohistochemical, and molecular appraisal

2010 ◽  
Vol 102 (1) ◽  
pp. 288-294 ◽  
Author(s):  
Zhiyan Liu ◽  
Gengyin Zhou ◽  
Misa Nakamura ◽  
Eisuke Koike ◽  
Yaqiong Li ◽  
...  
2011 ◽  
Vol 18 (5) ◽  
pp. 579-594 ◽  
Author(s):  
Sandra Lassalle ◽  
Véronique Hofman ◽  
Marius Ilie ◽  
Christelle Bonnetaud ◽  
Marie-Pierre Puisségur ◽  
...  

The term ‘thyroid tumors of uncertain malignant potential’ (TT-UMP) was coined by surgical pathologists to define well-differentiated tumors (WDT) showing inconclusive morphological evidence of malignancy or benignity. We have analyzed the expression of microRNA (miRNA) in a training set of 42 WDT of different histological subtypes: seven follicular tumors of UMP (FT-UMP), six WDT-UMP, seven follicular thyroid adenomas (FTA), 11 conventional papillary thyroid carcinomas (C-PTC), five follicular variants of PTC (FV-PTC), and six follicular thyroid carcinomas (FTC), which led to the identification of about 40 deregulated miRNAs. A subset of these altered miRNAs was independently validated by qRT-PCR, which included 18 supplementary TT-UMP (eight WDT-UMP and ten FT-UMP). Supervised clustering techniques were used to predict the first 42 samples. Based on the four possible outcomes (FTA, C-PTC, FV-PTC, and FTC), about 80% of FTA and C-PTC and 50% of FV-PTC and FTC samples were correctly assigned. Analysis of the independent set of 18 WDT-UMP by quantitative RT-PCR for the selection of the six most discriminating miRNAs was unable to separate FT-UMP from WDT-UMP, suggesting that the miRNA signature is insufficient in characterizing these two clinical entities. We conclude that considering FT-UMP and WDT-UMP as distinct and specific clinical entities may improve the diagnosis of WDT of the thyroid gland. In this context, a small set of miRNAs (i.e. miR-7, miR-146a, miR-146b, miR-200b, miR-221, and miR-222) appears to be useful, though not sufficient per se, in distinguishing TT-UMP from other WDT of the thyroid gland.


2014 ◽  
Vol 45 (3) ◽  
pp. 658-660 ◽  
Author(s):  
Pierre Bedossa ◽  
Alastair D. Burt ◽  
Elizabeth M. Brunt ◽  
Francesco Callea ◽  
Andrew D. Clouston ◽  
...  

2015 ◽  
Vol 10 (1) ◽  
Author(s):  
Monika Lamba Saini ◽  
Birgit Weynand ◽  
Jacques Rahier ◽  
Michel Mourad ◽  
Marc Hamoir ◽  
...  

2015 ◽  
Vol 46 (4) ◽  
pp. 634-635 ◽  
Author(s):  
Charles Balabaud ◽  
Paulette Bioulac-Sage ◽  
Linda Ferrell ◽  
Sanjay Kakar ◽  
Valérie Paradis ◽  
...  

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A894-A894
Author(s):  
Pedro Weslley Rosario ◽  
Gabriela Franco Mourão

Abstract Introduction: The diagnosis of thyroid tumors arising from follicular cells that are encapsulated/well delimited and noninvasive is a challenge. When unequivocal nuclear alterations are present, the final diagnosis can range from noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and classical/encapsulated papillary thyroid cancer (PTC), including aggressive subtypes, to poorly differentiated carcinoma. As proposed recently, the presence of papillae in the absence of exuberant nuclear alterations (nuclear score 2), given that the other criteria for NIFTP are met, may not be sufficient for the diagnosis of PTC. This condition is called “noninvasive encapsulated papillary RAS-like thyroid tumor” (NEPRAS), whose nature would be borderline and not malignant. Revising our cases of tumors > 1 cm that were diagnosed previously as PTC and that were encapsulated/well delimited and noninvasive, we found three cases of NEPRAS. We now revised our cases of tumors > 1 cm diagnosed previously as well-differentiated tumor of uncertain malignant potential (WDT-UMP) because the nuclear alterations were not considered to be sufficient for the diagnosis of PTC on that occasion. Case: In a 29-year-old euthyroid male patient with a single thyroid nodule whose fine-needle aspiration had revealed indeterminate cytology, a single tumor measuring 3.2 cm was reclassified from WDT-UMP to NEPRAS. For this diagnosis, the tumor met the following criteria: encapsulation or clear demarcation, no vascular or capsular invasion, presence of papillae, < 30% solid/trabecular/insular growth pattern, no tumor necrosis or high mitotic activity, and nuclear score 2. The BRAFV600E mutation was absent. The patient continues to show no signs of recurrence 7 years after lobectomy. Conclusion: Despite the presence of papillae, some tumors may be reclassified from malignant (encapsulated PTC) to borderline (NEPRAS). This proposal would result in a change of management, with the same implications as those seen for the change from noninvasive encapsulated follicular variant of PTC to NIFTP. References: Ohba K et al. Encapsulated Papillary Thyroid Tumor with Delicate Nuclear Changes and a KRAS Mutation as a Possible Novel Subtype of Borderline Tumor. J Pathol Transl Med. 2019;53:136-41 AND Rosario PW. Noninvasive encapsulated papillary RAS-like thyroid tumor (NEPRAS) or encapsulated papillary thyroid carcinoma (PTC). J Pathol Transl Med. 2020;54:263-4.


Sign in / Sign up

Export Citation Format

Share Document